Aegean Conferences is an independent, nonprofit, educational organization directed and managed by the scientific community. The board is made up of nine researchers/scientists in various disciplines from Harvard, Brown, University of Pennsylvania, UCSD, Princeton, Biovista and the Foundation for Biomedical Research Academy of Athens. The board both invites and approves unsolicited proposals for Conferences in all fields of Science, Engineering, Arts, and Humanities. The purpose of the Conferences is to bring together individuals with common interests to examine the emerging and most advanced aspects of their particular field. The Symposium on Ovarian Cancer: State of the Art and Future Directions intends to bring together international experts interested in the development of novel diagnostic, prognostic and therapeutic tools for ovarian cancer. The meeting will function as a think tank where clinicians, translational and basic scientists, and parties from the biotechnology and pharmaceutical industry will get together to review recent advances in clinical research and translational science in ovarian cancer and define areas of future research opportunities and priorities. TOC:Ovarian Cancer Detection and Pathogenesis.- 1. Potential and limitations in early diagnosis of Ovarian cancer.- 2. SMRP and HE4 as biomarker for Ovarian carcinoma.- 3. Classification of Ovarian cancer: A genomic analysis.- 4. Epigenetic markers of ovarian cancer.- 5. Role of genetic polymorphisms in ovarian cancer susceptibility: development of an international ovarian cancer association consortium.- 6. MicroRNA in human cancer: One step forward in diagnosis and treatment.- 7. Ovarian carcinogenesis, an alternative hypotheses.- 8. BRCA1 induced Ovarian oncogenesis.- 9. Role of p53 and Rb in ovarian cancer.- 10. Ovulatory factor in ovarian carcinogenesis.- Ovarian Cancer Therapeutics.- 11. Gynecologic Oncology group trials in Ovarian Cancer.- 12. Platinum Combinations for frontline chemotherapy of advanced ovarian carcinoma.- 13. Intraperitoneal chemotherapy of Ovarian Cancer.- 14. Ovarian cancer- can we reverse drug resistance?- 15. Nanoparticulate Paclitaxel, Nanotax, in ovarian cancer.- 16. Individualized molecular Medicine: Targeting the p13K pathway.- 17. Defective Apoptosis underlies chemoresistance in Ovarian Cancer.- 18. Nanoparticle delivery of suicide DNA for epithelial Ovarian cancer therapy.- 19. Biological therapy with oncolytic Herpes virus.- 20. Cancer immunotherapy: Perspectives and prospects.- 21. Regulatory T cells: A New Frontier in Cancer Immunotherapy.- 22. Inhibitory B7 family members in human ovarian carcinoma.- 23. Vascular leukocytes: a new target in ovarian cancer.- 24. Heparin-binding EGF-like growth factor as a new target molecule for cancer therapy.
Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.